Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial
- 1 August 2010
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 69 (8) , 1479-1483
Abstract
Objectives To determine whether baseline demographic, clinical, articular and laboratory variables predict methotrexate (MTX) poor response in polyarticular-course juvenile idiopathic arthritis. Methods Patients newly treated for 6 months with MTX enrolled in the Paediatric Rheumatology International Trials Organization (PRINTO) MTX trial. Bivariate and logistic regression analyses were used to identify baseline predictors of poor response according to the American College of Rheumatology pediatric (ACR-ped) 30 and 70 criteria. Results In all, 405/563 (71.9%) of patients were women; median age at onset and disease duration were 4.3 and 1.4 years, respectively, with anti-nuclear antibody (ANA) detected in 259/537 (48.2%) patients. With multivariate logistic regression analysis, the most important determinants of ACR-ped 70 non-responders were: disease duration >1.3 years (OR 1.93), ANA negativity (OR 1.77), Childhood Health Assessment Questionnaire (CHAQ) disability index>1.125 (OR 1.65) and the presence of right and left wrist activity (OR 1.55). Predictors of ACR-ped 30 non-responders were: ANA negativity (OR 1.92), CHAQ disability index>1.14 (OR 2.18) and a parent's evaluation of child's overall well-being ≤4.69 (OR 2.2). Conclusion The subgroup of patients with longer disease duration, ANA negativity, higher disability and presence of wrist activity were significantly associated with a poorer response to a 6-month MTX course.Keywords
This publication has 20 references indexed in Scilit:
- A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2008
- The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2008
- Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2008
- A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritisArthritis & Rheumatism, 2007
- Proxy‐reported health‐related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort studyArthritis Care & Research, 2007
- A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexateArthritis & Rheumatism, 2004
- Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritisArthritis & Rheumatism, 2003
- The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritisArthritis & Rheumatism, 2002
- Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritisBest Practice & Research Clinical Rheumatology, 2002
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997